Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (IGC Pharma, Inc.) on April 11, 2013. The report details a corporate action approved by the Board of Directors regarding the company's capital structure.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the post-split share count:
- Post-Split Outstanding Shares: Approximately 6,980,124 basic shares.
- Reverse Split Ratio: 10-for-1 (10 old shares exchanged for 1 new share).
- New CUSIP: 45408X 308.
Material Changes
The material change reported is the adoption of a 10-for-1 reverse stock split. Key details include:
- Effective Date: April 19, 2013.
- Warrants and Options: Adjusted such that 10 warrants or options will entitle the holder to one share upon exercise.
- Fractional Shares: No fractional shares will be issued; cash in lieu (CIL) will be paid instead.
- Ownership: Shareholder percentage ownership and voting power remain essentially unchanged.
Outlook, Management Commentary, and Risks
Management Rationale: The Board implemented the split to regain compliance with NYSE MKT listing requirements and to make the capital structure more attractive to microcap funds.
Expected Impact: Management expects the market price to increase tenfold, theoretically in inverse proportion to the split ratio. They hope this will encourage interest from microcap funds and improve liquidity.
Risks and Contingencies: The company explicitly states it cannot guarantee that the stock price will increase as expected or that liquidity will improve. The effect on the market price cannot be accurately predicted.
Investor Verification Checklist
- Verify the effective date of the reverse split (April 19, 2013) for trading purposes.
- Confirm the new CUSIP number (45408X 308) for account updates.
- Check if physical stock certificates need to be exchanged with the transfer agent.
- Review the treatment of fractional shares (cash in lieu) if holding a non-multiple of 10 shares.
- Monitor subsequent filings to confirm if NYSE MKT compliance was successfully achieved.